EVerZom works towards the democratization of regenerative medicine, using biological sub-cellular tools – extracellular vesicles – which are considered as an efficient and safer alternative to cell therapies. EVerZom, a spin off from a CNRS/Paris University laboratory, has developed and patented an innovative process which enables a high yield, GMP compatible and fast-foward production of extracellular vesicles at large scale by applying turbulence stimulation on the cells. The main objective of EVerZom and its bioproduction platform is to support researchers from the pharmaceutical industry to design and manufacture EV based therapies to treat ageing and inflammatory diseases.

Contact : jeanne.volatron@everzom.com